Section Arrow
CRVO.NASDAQ
- CervoMed
Quotes are at least 15-min delayed:2025/09/05 13:55 EDT
Regular Hours
Last
 10.5218
+0.3118 (+3.05%)
Day High 
10.74 
Prev. Close
10.21 
1-M High
11.25 
Volume 
67.23K 
Bid
10.33
Ask
10.6
Day Low
9.9738 
Open
10.26 
1-M Low
8.76 
Market Cap 
88.85M 
Currency USD 
P/E 4.66 
%Yield -- 
10-SMA 9.67 
20-SMA 9.65 
50-SMA 8.4 
52-W High 20.63 
52-W Low 1.8 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.63/-2.28
Enterprise Value
88.85M
Balance Sheet
Book Value Per Share
3.84
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ADAPAdaptimmune Therapeutics plc0.0485-0.0025-4.90%-- 
NUVBNuvation Bio3.945+0.525+15.35%-- 
IOVAIovance Biotherapeutics2.3859+0.1859+8.45%-- 
RXRXRecursion Pharmaceuticals4.585+0.065+1.44%-- 
MRNAModerna25.27+0.99+4.08%-- 
Quotes are at least 15-min delayed:2025/09/05 13:55 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction,the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.